PRAC Safety-Signal Labeling Updates — June 2026 PRAC Meeting

The European Medicines Agency (EMA), through the Pharmacovigilance Risk Assessment Committee (PRAC), adopted new safety-signal recommendations during its 8–11 June 2026 meeting, requiring Marketing Authorization Holders (MAHs) to update product information, including the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL). The recommendations include revised safety wording, adverse-event communication updates, and risk-minimization measures associated with evaluated medicinal products. The guidance reinforces EMA expectations for rapid implementation of safety variations and harmonized CCDS-to-local labeling alignment across EU member states. MAHs are expected to initiate the relevant Article 61(3) or Type II variation procedures within 30–60 days of signal adoption to reflect the updated product information across all applicable markets.